CRISPR finds drug synergy – Nature.com
|
CRISPR finds drug synergy
Nature.com Certain combinations of drugs might kill drug-resistant tumours, and a method based on the CRISPR–Cas9 gene-editing system offers a way to find them. Tumours often become resistant to individual drugs, leading clinicians to use combinations of … |
|
BASF Licenses CRISPR/Cas9 From Broad Institute for Ag-Bio, Industrial Microbe Applications
GenomeWeb NEW YORK (GenomeWeb) – BASF announced it has reached a non-exclusive, worldwide licensing agreement with the Broad Institute for CRISPR/Cas9 genome editing in ag-bio and industrial applications. “We are eager to see the new ways it will augment … |
OncLive |
Dr. Slovin on the Role of Immunotherapy for Prostate Cancer
OncLive The FDA approval of sipuleucel-T (Provenge) represented the first successful immunotherapy for a solid tumor that showed a survival benefit. All approaches that have been done subsequently are attempting to look at other ways of using the body’s immune … |
Life Science Leader Magazine |
Cross-Lab Data Collaborations – The Future Of Immunotherapy?
Life Science Leader Magazine In the field of immunotherapy, a handful of Big Pharma companies have been racing to achieve first or second line approval of their own checkpoint inhibitors in a small set of indications, including nonsmall cell lung cancer and bladder cancer … |